ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
19 hedge funds and large institutions have $8.17M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
5% less funds holding
Funds holding: 20 → 19 (-1)
6.82% less ownership
Funds ownership: 46.63% → 39.81% (-6.8%)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
26% less capital invested
Capital invested by funds: $11M → $8.17M (-$2.81M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$828K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$506K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$336K |
| 4 |
FTUS
Flow Traders U.S.
New York
|
+$288K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
BCWM LLC
Overland Park,
Kansas
|
-$4.1M |
| 2 |
CG
Colony Group
Boston,
Massachusetts
|
-$317K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$148K |
| 4 |
CA
CoreCap Advisors
Southfield,
Michigan
|
-$138K |
| 5 |
Citigroup
New York
|
-$32K |
CNCR Hedge Fund Activity: Q3 2022 in Review
19 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q3 2022, worth a combined $8.17M — down 26% from $11M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CNCR and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Jane Street, opening a new position worth an estimated $828K. The largest seller was BCWM LLC, cutting an estimated $4.1M.
- 19 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q3 2022, down from 20 in Q2 2022.
- Funds reported $8.17M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q3 2022, down 26% quarter-over-quarter.
- 4 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q3 2022 and 5 closed out, a net change of -1 holder.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q3 2022 was Jane Street, an estimated $828K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q3 2022 was BCWM LLC, an estimated $4.1M sold.
Based on aggregated 13F filings for Q3 2022.